Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company focused on discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis). The companyâs products include AT-101, a pan Bcl-2 inhibitor that directly induces apoptosis by operating as a BH3 mimetic and indirectly as a p53-independent upregulator of Noxa and Puma; AT-406, a multi-inhibitor of apoptosis protein (IAP) antagonist that promotes programmed cell death (apoptosis) in tumor cells by blocking the activity of inhibitors of apoptosis proteins or IAPs, such as XIAP, c-IAP1, c-IAP2, and ML-IAP to create conditions in which apoptosis can proceed; and Human double Minute 2, a protein that regulates the activity of p53 tumor suppressor protein. Ascenta Therapeutics, Inc. has a strategic collaboration with Ascentage Pharma Group Corporation. Ascenta Therapeutics, Inc. was formerly known as ACCU Therapeutics, Inc. and changed its name in April, 2004
